We are live on ! Find out more
PTCT icon

PTC Therapeutics
PTCT

129 hedge funds and large institutions have $715M invested in PTC Therapeutics in 2017 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

66% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 32

16% more capital invested

Capital invested by funds: $615M → $715M (+$101M)

13% more funds holding

Funds holding: 114 → 129 (+15)

5.05% more ownership

Funds ownership: 81.32% → 86.37% (+5.1%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

52% less call options, than puts

Call options by funds: $41.2M | Put options by funds: $86.1M

Holders
129
Holders Change
+15
Holders Change %
+13.16%
% of All Funds
3.22%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
29
Increased
53
Reduced
32
Closed
13
Calls
$41.2M
Puts
$86.1M
Net Calls
-$44.9M
Net Calls Change
-$54.1M

Top Buyers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
+$23.4M
2
DAM
DLD Asset Management
New York
+$12M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$11.1M
4
NI
Numeric Investors
Massachusetts
+$9.22M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.89M

Top Sellers

Rank Fund Capital Flow
1
FCM
Frontier Capital Management
Massachusetts
-$20.8M
2
GPP
Great Point Partners
Connecticut
-$15.7M
3
Morgan Stanley
Morgan Stanley
New York
-$9.26M
4
CCM
Camber Capital Management
Massachusetts
-$9.16M
5
BC
Boxer Capital
California
-$8.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$5.65M +$1.08M +54,973 +24%
Millennium Management
27
Millennium Management
New York
$5.21M +$5.1M +260,633 New
Invesco
28
Invesco
Georgia
$5.09M +$4.64M +236,880 +1,348%
FCM
29
Frontier Capital Management
Massachusetts
$4.95M -$20.8M -1,064,509 -81%
QI
30
QS Investors
New York
$4.59M -$108K -5,497 -2%
American Century Companies
31
American Century Companies
Missouri
$3.94M +$3.85M +196,722 New
MCM
32
Matarin Capital Management
New York
$3.74M +$714K +36,472 +24%
PCM
33
Prelude Capital Management
New York
$3.63M -$1.97M -100,845 -36%
Charles Schwab
34
Charles Schwab
California
$3.58M +$477K +24,366 +16%
Fisher Asset Management
35
Fisher Asset Management
Washington
$3.46M +$1.63M +83,403 +93%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.43M +$185K +9,469 +6%
SAM
37
Sectoral Asset Management
Quebec, Canada
$3.41M +$2.15M +109,800 +181%
SDIC
38
South Dakota Investment Council
South Dakota
$3.16M -$462K -23,611 -13%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$2.76M +$1.47M +75,240 +120%
Axa
40
Axa
France
$2.67M -$552K -28,200 -17%
Morgan Stanley
41
Morgan Stanley
New York
$2.08M -$9.26M -473,167 -82%
TCIM
42
TIAA CREF Investment Management
New York
$2.03M +$203K +10,373 +11%
GTC
43
Ghost Tree Capital
New York
$2M -$1.96M -100,000 -50%
OAM
44
Oxford Asset Management
United Kingdom
$1.9M +$1.88M +95,871 New
Group One Trading
45
Group One Trading
Illinois
$1.82M +$1.51M +77,023 +562%
3C
46
361 Capital
Colorado
$1.79M +$1.75M +89,600 New
Ameriprise
47
Ameriprise
Minnesota
$1.6M -$7.08M -361,512 -82%
Jane Street
48
Jane Street
New York
$1.58M +$1.54M +78,768 New
AQR Capital Management
49
AQR Capital Management
Connecticut
$1.47M +$451K +23,060 +46%
SSA
50
Schonfeld Strategic Advisors
New York
$1.38M +$1.35M +68,739 New
1
2
3 4 5

PTCT Hedge Fund Activity: Q3 2017 in Review

129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2017, worth a combined $715M — up 16% from $615M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PTCT positions and 13 closed out — a net gain of 16 holders — while 53 added to existing stakes and 32 trimmed.

The largest buyer was Scopia Capital Management, opening a new position worth an estimated $23.4M. The largest seller was Frontier Capital Management, cutting an estimated $20.8M.

  • 129 institutional investors held PTC Therapeutics (PTCT) as of Q3 2017, up from 114 in Q2 2017.
  • Funds reported $715M of PTC Therapeutics stock for Q3 2017, up 16% quarter-over-quarter.
  • 29 funds opened new PTC Therapeutics positions in Q3 2017 and 13 closed out, a net change of +16 holders.
  • The largest PTC Therapeutics buyer in Q3 2017 was Scopia Capital Management, an estimated $23.4M added.
  • The largest PTC Therapeutics seller in Q3 2017 was Frontier Capital Management, an estimated $20.8M sold.

Based on aggregated 13F filings for Q3 2017.